The EU butts heads with Big Pharma to make medicines cheaper

By HEOR Staff Writer

February 2, 2023

The new EU proposal to revamp its pharmaceutical regulations. The main aim is to give people a better and more affordable access to medicines.

From what I can see, there are mixed feelings about the proposal. On one hand, consumer groups and civil society organizations are applauding the EU’s efforts to make medicines more accessible. On the other hand, the pharmaceutical industry is a bit skeptical.

So, what’s in the proposal? Well, the EU is looking to shorten the period in which pharmaceutical companies can sell their medicines without competition from 10 years to just 8 years. They’re also working towards closing the gap in access to medicines among different EU member states.

It’s interesting to see how this will all play out. What are your thoughts on the EU Pharmaceutical Regulations Proposal?

Reference url

Recent Posts

AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025

By João L. Carapinha

February 11, 2026

AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadershi...
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes

By HEOR Staff Writer

February 10, 2026

Unlocking Early-Stage Cancer Treatment Gains Early-stage cancer treatment offers significant clinical, humanistic, and economic advantages through timely detection and intervention, yet faces barriers like screening disparities, recurren...
European Pharma Competitiveness: A Cornerstone for EU Economic Resilience

By João L. Carapinha

February 9, 2026

European Pharma Competitiveness: Driving EU Economic Strength European pharma competitiveness is vital for the EU's trade surplus and future growth. How does the pharmaceutical sector boost EU competitiveness? It generate...